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Abstract
Background: With the persistent challenges towards controlling the HIV epidemic, there is an ongoing need for research
into HIV vaccines and drugs. Sub-Saharan African countries - worst affected by the HIV pandemic - have participated in the
conduct of clinical trials for HIV vaccines. In Kenya, the Kenya AIDS Vaccine Initiative (KAVI) at the University of Nairobi has
conducted HIV vaccine clinical trials since 2001.
Methodology: Participants were recruited after an extensive informed consent process followed by screening to determine
eligibility. Screening included an assessment of risk behavior, medical history and physical examination, and if clinically
healthy, laboratory testing. In the absence of locally derived laboratory reference ranges, the ranges used in these trials were
derived from populations in the West.
Principal findings: Two hundred eighty-one participants were screened between 2003 and 2006 for two clinical trials. Of
these, 167 (59.4%) met the inclusion/exclusion criteria. Overall, laboratory abnormalities based on the non-indigenous
laboratory references used were the most frequent reasons (61.4%) for ineligibility. Medical abnormalities contributed 30.7%
of the total reasons for ineligibility. Based on the laboratory reference intervals now developed from East and Southern
Africa, those ineligible due to laboratory abnormalities would have been 46.3%. Of the eligible participants, 18.6% declined
enrolment.
Conclusions: Participant recruitment for HIV vaccine clinical trials is a rigorous and time-consuming exercise. Over 61% of
the screening exclusions in clinically healthy people were due to laboratory abnormalities. It is essential that laboratory
reference ranges generated from local populations for laboratory values be used in the conduct of clinical trials to avoid
unnecessary exclusion of willing participants and to avoid over-reporting of adverse events for enrolled participants.
Trial registration: Protocol IAVI VRC V001 [1]. ClinicalTrials.gov NCT00124007 Protocol IAVI 010 [2] (registration with
ClincalTrials.gov is in progress) Protocols IAVI 002 and IAVI 004 are Phase 1 trials only mentioned in introductory
paragraphs; details will not be reported. Registration was not required when they were conducted.
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Introduction
The majority of the people living with HIV are in sub-Saharan
Africa (68%) with some countries having disturbingly high HIV
prevalence rates. In 2009, Sub-Saharan Africa had an overall HIV
prevalencerate of 5%[3].In some populations, the HIVprevalence
rate is much higher than average; for example in 2009 the
prevalence rates for Botswana were 24.8%, for South Africa 17.8%,
and for Swaziland 25.9% [3]. Although the current control
measures may have lowered the HIV prevalence in some countries,
scientists generally believe that a safe, effective, accessible and
affordable preventive HIV vaccine is the best hope for stopping the
HIV epidemic. In this regard, sub-Saharan Africa, which endures
most of the HIVepidemic,mustplay its rightfulroleinresearch and
development, not only of preventive HIV vaccines, but also
discovery and development of new anti-retroviral drugs.
Several African countries have participated in HIV vaccine
research. Since 2001, the Kenya AIDS Vaccine Initiative (KAVI)
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e14580at University of Nairobi (Kenya) has conducted three phase 1 and
one phase 2A HIV vaccine clinical trials.
The phase 1 trials tested the following:
N an HIV clade A plasmid DNA (pTHr.DNA.HIVA) vaccine -
Protocol IAVI 002 (2001) [4,5,6]
N a recombinant vaccine vectored by modified vaccinia virus
Ankara (MVA); MVA.HIVA - Protocol IAVI 004 (2002)
[4,5,6]
N the VRC recombinant replication-defective Adenovirus sub-
type 5-vectored multi-clade vaccine (Vaccine Research Center)
NIH, VRC HIV-1 rAd5), either alone or as boost following
VRC HIV-1 DNA vaccine - Protocol IAVI V001 (2006) [1]
The phase 2A trial tested the following:
N a plasmid DNA.HIVA as prime followed by MVA.HIVA as
boost – Protocol IAVI 010 (2003). [2,5,6]
To determine eligibility, potential participants in all these trials
went through a rigorous screening process, and were only enrolled
after meeting inclusion/exclusion criteria specific to the respective
study protocol. Generally, these requirements included healthy,
HIV negative, 18 to 50 year-old subjects, who had not participated
in any trial of an investigational product, and were willing and able
to give informed consent. In addition to an HIV risk assessment,
participants had clinical screening that included medical history,
medical examination and laboratory testing. Study specific
requirements included chest x-ray to exclude active tuberculosis
and stool microscopy for intestinal parasites in two early studies
conducted at KAVI [4,5]. These screening tests excluded few
subjects.
This paper examines the reasons potential participants were
ineligible for enrollment in two vaccine clinical trials conducted at
KAVI during the period 2003 to 2006, ie, Protocols 010 and
V001.
Materials and Methods
Ethics Statement
Scientific and ethical clearance to conduct these studies,
including the informed consent document, was obtained from
Kenyatta National Hospital/University of Nairobi Ethics and
Research Committee (KNH/UONERC). In addition, the V001
study protocol was reviewed and approved by the Pharmacy and
Poisons Board. As per the Kenyan requirements, the National
Council for Science and Technology received the protocols for
information.
Participant recruitment methods
The participant/volunteer recruitment involved the use of a
peer-leader approach, as well as electronic and print media. The
peer-leaders were members chosen according to the communities
they represented and were used to gain access to communities for
recruitment seminars. Information posters on the studies were
placed in public places, such as shopping centers and bus stations.
The informed consent process started with peer-leader-organized
informational seminars held in various communities, at institutions
of higher learning, such as polytechnics, medical training colleges,
and universities, and other organizations based in Nairobi. At
these seminars, those interested in participating in the clinical
vaccine trials were invited to a recruitment seminar at the study
site at KAVI. Those who attended the recruitment seminars were
then invited to individualized sessions with the study nurse-
counselors or physicians where detailed information on participa-
tion in the clinical trials was given, including discussion of the
informed consent document. During the sessions, individuals’
questions were answered comprehensively, and the participants
were provided the informed consent document to take home for
review. In addition, individuals were counseled on contraception
and low-risk behavior for HIV infection. These individualized
information sessions improved potential participants’ understand-
ing of the study’s requirements. Some of them, realizing they did
not qualify for the study, excluded themselves and thus did not
proceed further. Interested individuals were then scheduled for a
screening visit to assess their eligibility. On average, each
participant attended a recruitment seminar and three individual-
ized information sessions prior to the screening visit; this process
required about two weeks.
Screening procedures
A study nurse-counselor verified each participant’s identity and
age, reviewed the informed consent document with participants,
and then assessed their understanding of the trial using a standard
assessment of understanding questionnaire. Only those who passed
this assessment were allowed to participate in the trials and were
asked to provide a signed informed consent. Thereafter, a
screening questionnaire was administered and HIV risk assessment
performed. For participants who were determined to practice low-
risk behavior for HIV infection, the study physician obtained
medical history and performed a complete physical examination;
vital signs; height and weight; examination of skin, respiratory,
central nervous, cardiovascular, and abdominal systems; and an
assessment of cervical and axillary lymph nodes. Laboratory tests
were not performed on participants with any clinically significant
abnormality as determined from medical history or physical
examination. Individuals were excluded from the study if they had
history of immunodeficiency or autoimmune disease; or had used
systemic corticosteroids, immunosuppressive, antiviral, anticancer,
or other medications considered significant by the investigator
within the previous 6 months. They were also excluded if they had
any clinically significant acute or chronic medical condition that
was considered progressive, or in the opinion of the investigator,
would make the participant unsuitable for the study.
Participants who had normal findings from their medical history
and physical examination received pre-HIV-test counseling before
blood (venous) and urine specimen collection. Specimen collection
occurred between 0800 and 1400 hours. Hematology and clinical
chemistry assays were completed on the day of sample collection;
the other tests were performed within one week. All the assays
were performed at the KAVI Laboratory, Department of Medical
Microbiology in the University of Nairobi. This laboratory had
internal quality assurance systems in place and received interna-
tional Good Clinical and Laboratory Practice (GCLP) accredita-
tion in the year 2005. Laboratory personnel compiled results that
were reviewed by the laboratory manager and then dispatched to
the clinic within five days of sample collection. In the clinic, the
study physicians and nurses reviewed each participant’s screening
results to determine eligibility for enrolment. For the hematolog-
ical and clinical chemistry parameters, eligibility was determined
using a set of modified reference ranges derived from populations
in the US (Table 1) [7].
The hematology assays performed during screening included
white blood cell counts, red blood cell counts, differential, and
hemoglobin. Clinical chemistry assays included direct and total
serum bilirubin, alanine aminotransferase (ALT/SGPT), aspartate
aminotransferase (AST/SGOT), alkaline phosphatase, and serum
creatinine. Other tests included urinalysis, CD4 and CD8 cell
counts, HIV ELISA, Hepatitis B surface antigen, Hepatitis C
Reasons for Ineligibility
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Anti-ds DNA antibodies (ANA). In Protocol V001, laboratory
parameters did not include eosinophil counts, total or direct serum
bilirubin, alkaline phosphatase, AST (SGOT), or Anti-ds DNA.
Instrumentation and assays employed in the laboratory
assays
N Vitalab Selectra E Chemistry Analyzer: Vital Scientific,
Netherlands. Spectrophotometric, 32 analyte, open-system
analyzer.
N COULTERH Ac?T
TM 5diff OV: Beckman Coulter, Inc. Brea,
California, USA. 5-part differential analysis system employs
absorbance cytochemistry and Volume (AcV) technology.
N VironostikaH HIV-1 Antigen: Biomerieux, Inc, Durham, NC.
Microelisa test for the detection of p24 core HIV-1 antigen in
serum, plasma or culture supernatant (used in Protocol 010 only).
N VironostikaH HIV Uni-Form II Ag/Ab: Biomerieux, Inc,
Durham, NC. One step Microelisa test for the immunological
detection of HIV-1, HIV-1 Group O and HIV-2 infection
(used in Protocol V001 only).
N Detect HIV I/II
TM: Adaltis, Rome, Italy.
N Monolisa
TM HBs Ag ULTRA Assay: Bio-Rad Laboratories,
Inc, Hercules, California, USA. A one-step enzyme immuno-
assay for the detection of the surface antigen of the Hepatitis B
virus (HBs Ag) in human serum or plasma.
N INNOTESTH HCV Ab IV: Innogenetics Ltd, Gent, Belgium.
An enzyme immunoassay for the detection of antibodies to
human hepatitis C virus (HCV) in human serum or plasma.
N Antinuclear Antibody (ANA) Screen: DRG Diagnostics,
Germany. Enzyme immunoassay for the qualitative screening
on anti-ANA-antibodies in human serum or plasma.
Eligible participants were males and females 18 to 60 years of
age (18–50 years for Protocol V001) who passed the assessment of
understanding test and were willing and able to provide written
informed consent. They did not engage in behavior that was high-
risk for HIV infection; and were willing to undergo HIV
counseling and testing, and to receive HIV test results. They also
had to be willing to comply with the study procedures. Females
were not to be pregnant or breastfeeding and had to be willing to
prevent pregnancy during their participation in the trial.
High-risk behaviors for HIV infection within the previous 6
months as defined below were exclusionary:
N had unprotected vaginal or anal sex with a known HIV-
infected person or a casual partner (ie, no continuing
established relationship);
N engaged in sex work for money or drugs;
N used illicit drugs;
N acquired a sexually-transmitted disease (eg, Gonorrhea, Chlamyd-
ia, syphilis, Trichomonas vaginalis, or symptomatic Herpes genitalis);
Table 1. Comparison/consensus intervals for select hematology and biochemistry assays for US, Africa, and Protocols IAVI 010 and
V001.
Analytes
East/South Africa
Consensus Interval
+
US-Based Comparison
Interval*
Modified US
Comparison Interval** Units
Chemistry
Creatinine 47–109 0–133 55–133 mmol/L
AST (SGOT) 14–60 0–35 ,40 IU/L
ALT (SGPT) 8–61 0–35 ,40 IU/L
Bilirubin, direct 0.4–4.8 1.7–5.1 ,7 mmol/L
Bilirubin, total 2.9–37.0 5.1–17 ,17 mmol/L
Hematology
RBC: male & female 3.8–6.4 4.0–5.9 4.1–6.1 610
6 cells/mL
Hemoglobin: male 12.2–17.7 13.5–17.5 12–18 g/dL
Hemoglobin: female 9.5–15.8 12.0–16.0 12–18 g/dL
Hematocrit: male 35.0–50.8 41–53 34–52 %
Hematocrit: female 29.4–45.4 36–46 34–52 %
Platelets 126–438 150–350 130–550 610
3 cells/mL
Total WBC 3.1–9.1 4.5–11.0 3.3–11.0 610
3 cells/mL
Neutrophil count 1.0–5.3 1.8–7.7 1.5–8.0 610
3 cells/mL
Neutrophil (%) 25–66 40–70 45–75 %
Lymphocyte count 1.2–3.7 1.0–4.8 0.8–4.9 610
3 cells/mL
Lymphocyte (%) 23–59 22–44 16–50 %
Monocyte (%) 4.5–13.1 4–11 4–11 %
Eosinophil (%) 0.8–21.8 0–8 0–8 %
CD4 count 457–1628 518–1981 518–1981 Cells/mL
CD8 count 230–1178 270–1335 270–1335 cells/mL
+ From Karita E, et al [8].
*From Kratz A, et al [7].
**Comparison intervals for Protocols 010 and V001.
doi:10.1371/journal.pone.0014580.t001
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previous 6 months (Protocol V001 only).
With regard to laboratory parameters, the participants were
required to be negative for HIV Ab, hepatitis C Ab, syphilis
serology, hepatitis B surface antigen, ANA; and for females, urine
pregnancy test. Eligible participants were required to have normal
hematology, biochemistry, CD4, and CD8 cell counts according to
designated laboratory reference ranges, as well as normal
urinalysis. For Protocol 010, mild/grade 1 abnormalities found
in hematology, biochemistry, and urine parameters that were
judged as not clinically significant by the principal investigator
were allowed. In Protocol V001, mild/grade 1 elevations of ALT
(SGPT), ie, elevated .1.256upper limit of normal (ULN), mildly
reduced neutrophil counts (up to 1001 cells/mm
3), mildly reduced
platelet counts (up to 125 cells/mm
3), and mildly reduced
hemoglobin values (11 g/dL) in females were permitted. Eosino-
phil counts, serum AST (SGOT), alkaline phosphatase, and total
and direct bilirubin assays were eliminated from the screening tests
for Protocol V001. Protocol V001 required that at least 30% of the
enrolled volunteers be female.
Acute and minor abnormalities detected during the screening,
such as upper respiratory tract infections and urinary tract
infections were medically managed at the research centre.
Conditions requiring follow-up, such as a cardiac murmur or
hepatitis B infection, were referred to a nearby national referral
hospital, the Kenyatta National Hospital, in Nairobi.
Clinic and laboratory personnel who were trained in GCP and
GCLP, respectively, conducted all clinical trials according to
ICH/GCP guidelines and the site’s standard operating
procedures.
Results
For comparative purposes, Table 1 provides the consensus
intervals for chemistry and hematology parameters for healthy
adults in East and South Africa [8], the US-based comparison
intervals used in that study [7], along with comparison intervals
used for Protocols 010 and V001. Only a subset of all laboratory
parameters is included.
Two hundred eighty-one participants were screened between
the years 2003 and 2006 for the two referenced clinical trials
(Figure 1). Of these, 167 (59.4%) were eligible for participation
based on inclusion and exclusion criteria; there were 105 (62.9%)
males and 62 (37.1%) females. Of those eligible, 127 (76.0%) were
enrolled: 94 (74.0%) males and 33 (26.0%) females. Thirty-one
(18.6%) of the eligible volunteers declined enrolment in the clinical
trials. The majority of these 23/31 (74.2%) were females and most
were from Protocol V001 (Figure 1). The recruitment rate
averaged 13 volunteers per month for Protocol 010 and 14 for
Protocol V001.
Those who were excluded (61.4%) because of abnormal
biochemical or hematology values had no other diagnosed clinical
condition (Table 2). Medical abnormalities and other conditions
accounted for the remaining 38.6% of exclusions.
Medical abnormalities alone accounted for 35 (30.7%) of all the
reasons for ineligibility. Fifteen were excluded because of medical
history and physical examination findings including allergy,
bronchial asthma, and cardiac conditions. Serologic tests led to
exclusion of an additional 20 (17.5%) participants: 9 HIV, 7
hepatitis B/C, and 4 ANA. In Protocol V001, 14.7% and 20.6%
of exclusions were due to hepatitis B or C and HIV infections,
respectively (Table 2). Other reasons for ineligibility in both
Figure 1. Disposition, by gender, of participants screened in two HIV vaccine clinical trials conducted in Nairobi.
doi:10.1371/journal.pone.0014580.g001
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reports of high-risk behavior for HIV infection (5), inability to
comply with study visit schedules (3), and pregnancy (1).
Thirty-six (31.6%) of the total exclusions in the two studies were
because of abnormal hematology values alone, with neutropenia
accounting for the majority of these. Abnormal biochemistry
values alone accounted for 34 of the 114 (29.8%) total exclusions
(Table 2). Of 55 participants screened out through laboratory
testing for Protocol 010, 28 (50.9%) had hyperbilirubinemia
(Table 3).
Nineteen of the 28 participants with abnormal total bilirubin
values and 11 of 20 with neutropenia would have been eligible had
the East/South Africa consensus intervals been used (Table 4). All
of these participants were from Protocol 010.
Discussion
Participant recruitment for HIV clinical trials is a difficult and
rigorous process that is very demanding of staff time and financial
resources. The participant recruitment rates for Protocols 010 and
V001 were approximately three times faster than the studies
completed in 2001 and 2002 [6]. This was likely due to lessons
learned with recruitment.
The main reasons for ineligibility during volunteer screening for
the clinical trials included abnormal laboratory parameters and
medical abnormalities. Abnormal hematology and biochemistry
values contributed the most (61.4%) to screen failures in otherwise
clinically healthy participants. The high rate of exclusions based
on laboratory parameters raises some questions: Could there have
been un-diagnosed co-morbidities? Were the laboratory reference
ranges unrealistic for this population?
Not all possible endemic co-morbidities were included when
screening, such as helminthiasis and malaria. It is possible that
some of these may have contributed to some of the laboratory
abnormalities noted. For instance, in one study among adult
African volunteers from East and Southern Africa, possible
malaria accounted for 6% of exclusions [9].
It is worth noting that most of the abnormalities in total
bilirubin and neutrophil counts were not in combination with
other abnormal laboratory parameters as would be expected if the
causes were undiagnosed clinical conditions. Of the 28 partici-
pants with abnormally increased total bilirubin results, there were
only 4 with abnormal liver function test values (increased alkaline
phosphatase) hence for the majority, reduced uptake of bilirubin
due to liver pathology is an unlikely explanation. Hemolysis is also
an unlikely explanation because none of the participants with
elevated total serum bilirubin was clinically jaundiced or had
abnormal red cell indices.
The notable difference in the contribution of hematology and
biochemistry to the overall laboratory abnormalities between
Protocol 010 (68.8%) and Protocol V001 (44.1%) as seen in
Table 2 is mostly due to the removal of total serum bilirubin,
alkaline phosphatase, CD4 cell count, and eosinophil assays from
the screening laboratory parameters for the Protocol V001.
Having realized from earlier studies that elevated total serum
bilirubin or eosinophilia in many individuals from this population
were not clinically significant, these assays were not included in the
screening tests. Yet, the average monthly recruitment rate of
participants in the two protocols remained similar and was better
than that of earlier studies in which Omosa, et al[6], reported
recruitment rates of approximately 4 to 5 participants per month.
Further studies to determine reasons for the improvement in the
recruitment speed need to be carried out to better plan for future
recruitment strategies, especially for the larger Phase 3 trials.
Because of poor access and the expense, people in developing
countries do not routinely seek medical attention unless signs and/
or symptoms of disease appear. The presence of asymptomatic co-
morbidities, such as intestinal helminthiasis, in such a population
cannot be ruled out; however, it would not be practical to
routinely screen for all potential co-morbidities during the conduct
of a clinical trial, especially during phase III trials involving large
numbers. Furthermore, when the next candidate HIV vaccine
becomes available for testing, potential participants should not be
excluded because of such minor variations. In such a situation, a
clinically ‘normal’ population would include those with suspected/
assumed asymptomatic co-morbidities. Studies have also shown
Table 2. Reasons for ineligibility in two HIV vaccine clinical
trials in Nairobi.
Number Ineligible by Protocol (n)
010 V001 Total
Reasons for Ineligibility (80) (34) (114)
Medical abnormality – n (%) 20 (25.0) 15 (44.1) 35 (30.7)
Clinical history/PE 12 (15) 3 (8.8) 15 (13.2)
HIV Positive – n (%) 2 (2.5) 7 (20.6) 9 (7.9)
Hep B/C positive – n (%) 2 (2.5) 5 (14.7) 7 (6.1)
ANA – n (%) 4 (5.0) NA 4 (3.5)
Laboratory abnormality – n (%) 55 (68.8) 15 (44.1) 70 (61.4)
Hematology – n (%) 23(28.8) 13 (38.2) 36 (31.6)
Biochemistry – n (%) 32(40.0) 2 (5.9) 34 (29.8)
Other reasons n – n (%) 5 (6.3) 4 (11.8) 9* (7.9)
*1 pregnancy, 5 high-risk behavior, 3 unable to comply with visit schedule.
PE= physical examination.
doi:10.1371/journal.pone.0014580.t002
Table 3. Ineligibility due to abnormal hematology and
biochemistry values in two HIV vaccine clinical trials.
010 V001 Total
Parameter – n (%) n=55 n=15 n=70
Hematology
Low hemoglobin 1 (1.8) 4 (26.7) 5 (7.1)
Leucopenia 1 (1.8) 0 1 (1.4)
Neutropenia 11*(20.0) 9 (60.0) 20 (28.6)
Eosinophilia 6 (10.9) NA 6 (8.6)
Low CD4 counts 4 (7.3) NA 4 (5.7)
Total Hematology 23 (41.8) 13 (86.7) 36 (51.4)
Biochemistry
Elevated total bilirubin 28
+(50.9) NA 28 (40)
Elevated ALT 1 (1.8) 2**(13.3) 3 (4.3)
Alkaline phosphatase 3 (5.5) NA 3 (4.3)
Total Biochemistry 32 (58.2) 2 (13.3) 34 (48.6)
*Two cases had concurrent leucopenia.
+Five cases were due to high total serum bilirubin and neutropenia; 4 had
elevated alkaline phosphatase.
**ALT elevated .1.256ULN.
doi:10.1371/journal.pone.0014580.t003
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diet, altitude, race, gender, and age [8,10,11,12,13,14,15].
Therefore, using laboratory reference ranges derived from
populations in industrialized countries to assess participant
eligibility and safety for clinical trials in an African population
could lead to unnecessary exclusion of otherwise eligible
participants and contribute to over-reporting of adverse events.
Had the East/South Africa consensus intervals [8,9] been used for
reference, 32 of previously ineligible participants would have
qualified for these two studies (Table 4); this would have lead to an
overall exclusion rate due to abnormal laboratory parameters of
46.3% (38/82) in contrast to 61.4% (Table 2). At the time these
studies were conducted, Karita, et al [8], had not yet reported
their data establishing consensus ranges for adults in East and
South Africa.
To lose otherwise qualified participants because of laboratory
values that are considered abnormal by reference standards from
another part of the world has significant impact on resources and
requires further consideration. Thus, it is essential that laboratory
reference ranges generated from local populations be used to
conduct clinical trials, as well as to manage patient care.
Although the participants screened were considered to be low
risk for HIV and other sexually transmitted infections (STI), the
rates of hepatitis B or C and HIV infections were relatively high.
Such findings call for review of the HIV/STI risk assessment tool
employed in selecting low-risk participants for such trials. Worth
noting, there was only one pregnancy at screening in this
population, likely due to self-selection of subjects after pre-trial
counseling and education sessions when potential participants
became fully aware of the study requirements. Interestingly, there
seems to have been less self-exclusion of HIV sero-positive
participants, which points to a general lack of knowledge regarding
self-HIV status in this population at the time. It is hoped that with
the ongoing HIV voluntary counseling and testing, and provider-
initiated counseling and testing campaigns in Kenya, self-
knowledge of HIV sero-status has since improved.
Other challenges pertaining to participant recruitment became
evident: the high numbers of eligible participants declining
enrolment and the low female: male ratio (Figure 1). Some of
the declines were due to negative influences from peers; most were
females. There was a low female: male ratio in the Protocol 010, in
which there was no minimum requirement for female represen-
tation (Figure 1). The requirement that female participants should
not be pregnant or breastfeeding during participation may have
partly contributed to this; other cultural and practical influences
may also have impacted female participation. These observations
need further study.
In addition, some potential participants were greatly disap-
pointed when they learned they did not qualify for enrolment in
the trials. Individuals who appear eager to participate are more
likely to continue and complete a trial. Using reference ranges
established from local populations would avoid unnecessary
exclusion of some of these otherwise willing participants.
Acknowledgments
1. All the volunteers that participated in the clinical trials.
2. Colleagues at Kenya AIDS Vaccine Initiative (KAVI), University of
Nairobi, Kenya.
3. Colleagues as International AIDS Vaccine Initiative (IAVI).
4. Randall Kaja (Pfizer Global Health Fellow) for editorial support.
5. Barry Peters, Job Bwayo, Barney Graham for their contributions in
designing the studies.
Author Contributions
Conceived and designed the experiments: CS PF. Performed the
experiments: GSOM WJ OA HO SW RM JN PN JONA KB BF
MOO. Analyzed the data: GSOM WJ OA HO SW RM JN PN JONA KB
BF MOO CS FP PF. Wrote the paper: GSOM. Reviewed the paper: WJ
OA HO SW RM JN PN JONA KB BF MOO CS FP PF.
References
1. Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, et al. (2010)
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine
alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS
ONE 5: e12873.
2. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, et al. (2007) Studies
of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus
Ankara (MVA) with and without DNA priming: effects of dosage and route on
safety and immunogenicity. Vaccine 25: 2120–2127.
3. UNAIDS (2010) Report on the global HIV/AIDS epidemic. Geneva.
4. Jaoko W, Nakwagala FN, Anzala O, Manyonyi GO, Birungi J, et al. (2008)
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine
candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara
(MVA) in humans in East Africa. Vaccine 26: 2788–2795.
5. Omosa G, Jaoko W, Wakasiaka S, Ogutu H, Bwayo J (2002) Volunteer
Recruitment for phase 1 HIV Vaccine Trials in Nairobi. Baltimore, Maryland,
USA: 5th Annual Conference on Vaccine Research.
6. Omosa-Manyonyi G, Jaoko W, Wakasiaka S, Bwayo J, Ndinya-Achola J, et al.
(2005) Challenges experienced by the clinical team during the conduct of HIV
vaccine clinical trials in Kenya. Montreal, CANADA: AIDS Vaccine
2005.
7. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB (2004) Case records of the
Massachusetts General Hospital. Weekly clinicopathological exercises. Labora-
tory reference values. N Engl J Med 351: 1548–1563.
Table 4. Participants with selected laboratory abnormalities: those who would have qualified using East/South Africa consensus
intervals.
East/South
Africa Consensus
Interval *
Modified US
Comparison
Interval
Number Ineligible
per US Comparison
Interval
Number Ineligible per
East/South Africa
Consensus Interval
Number projected
eligible per East/
South Africa Interval
Total Bilirubin (mmol/L) 2.9–37.0 ,17 28 9 19
+
Neutropenia (610
3 cells/mL) 1.0–5.3 1.5–8.0 20 9 11
Total WBC (610
3 cells/mL) 3.1–9.1 3.3–11.0 1 0 1
Hemoglobin: female (g/dL) 9.5–15.8 12–18 5 4 1
Total 54 22 32
*From Karita, et al, [8].
+Total bilirubin was .17 and ,25.5 mmol/L for 12 participants and .25.5 and ,37 mmol/L for 7 participants.
doi:10.1371/journal.pone.0014580.t004
Reasons for Ineligibility
PLoS ONE | www.plosone.org 6 January 2011 | Volume 6 | Issue 1 | e145808. Karita E, Ketter N, Price MA, Kayitenkore K, Kaleebu P, et al. (2009) CLSI-
derived hematology and biochemistry reference intervals for healthy adults in
eastern and southern Africa. PLoS ONE 4: e4401.
9. Stevens W, Kamali A, Karita E, Anzala O, Sanders EJ, et al. (2008) Baseline
morbidity in 2,990 adult African volunteers recruited to characterize laboratory
reference intervals for future HIV vaccine clinical trials. PLoS ONE 3: e2043.
10. Kasili EG, Cardwell CL, Taylor JR (1969) Leucocyte counts on blood donors in
Nairobi. East Afr Med J 46: 676–679.
11. Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, et al. (2004)
Population-based hematologic and immunologic reference values for a healthy
Ugandan population. Clin Diagn Lab Immunol 11: 29–34.
12. Ezeilo GC (1972) Non-genetic neutropenia in Africans. Lancet 2: 1003–1004.
1 3 .T s e g a y eA ,M e s s e l eT ,T i l a h u nT ,H a i l uE ,S a h l uT ,e ta l .( 1 9 9 9 )
Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab
Immunol 6: 410–414.
14. Menard D, Mandeng MJ, Tothy MB, Kelembho EK, Gresenguet G, et al.
(2003) Immunohematological reference ranges for adults from the Central
African Republic. Clin Diagn Lab Immunol 10: 443–445.
15. Shaper AG, Lewis P (1971) Genetic neutropenia in people of African origin.
Lancet 2: 1021–1023.
Reasons for Ineligibility
PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e14580